Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $35.2052W HIGH $82.94
Volume
430.28 K
Value Traded
20.30 M
Short % Float
8.61%
+5.26%Week
+1.6%1 Month
+25.76%3 Month
+69.46%6 Month
+265.66%5 Year
+117.75%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.22 B
EPS (TTM)
1.03
P/E Ratio
77.17
Ent. Value
5.70 B
Total Shares
78.02 M
Float Shares
45.02 M
Insiders
42.30%
Institutions
60.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
KNSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Kiniksa Pharmaceuticals International, plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kiniksa Pharmaceuticals International, plc
240Total events
5Upcoming
59Tier-1 (high impact)
2018 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Oral PresentationPresentation
Kiniksa management to present at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Kiniksa management to present at Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Management to participate in fireside chats at June 2026 investor conferences
▲Quarterly UpdateARCALYSTApprovedCorporate
2026 ARCALYST net product revenue guidance raised to $930-$945 million
recurrent pericarditissource ↗
▲Product LaunchARCALYSTApprovedPost-Market
Launch of Heart's Home DTC campaign for ARCALYST in recurrent pericarditis
recurrent pericarditissource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2025 financial results and recent portfolio execution
●Oral PresentationPresentation
Corporate presentation at 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
●Quarterly UpdateCorporate
Kiniksa provides corporate update with 2025 financials and 2026 guidance
▲Quarterly UpdateARCALYSTApprovedCorporate
ARCALYST 2025 net product revenue of $677.5 million
recurrent pericarditissource ↗
◆Oral PresentationPresentation
Kiniksa management to present at Jefferies Global Healthcare Conference in London
◆Quarterly UpdateCorporate
Third quarter 2025 financial results and recent portfolio execution conference call
▲Quarterly UpdateARCALYSTApprovedCorporate
2025 ARCALYST net product revenue guidance raised to $670-$675 million
recurrent pericarditissource ↗
▲Orphan Drug DesignationKPL-387Designation
FDA granted Orphan Drug Designation to KPL-387 for pericarditis
pericarditissource ↗
▲Orphan Drug DesignationKPL-387Designation
FDA granted Orphan Drug Designation to KPL-387 for pericarditis in October 2025
pericarditissource ↗
◆Oral PresentationPresentation
Management to participate in fireside chats at investor conferences in September 2025
◆Quarterly UpdateCorporate
Second Quarter 2025 Financial Results and Recent Portfolio Execution
▲Quarterly UpdateARCALYSTApprovedCorporate
ARCALYST 2025 net product revenue guidance raised to $625-$640 million
recurrent pericarditissource ↗
▲Trial InitiationKPL-387Trial
KPL-387 Phase 2/3 clinical trial in recurrent pericarditis initiated
recurrent pericarditissource ↗
◆Oral PresentationPresentation
Goldman Sachs 46th Annual Global Healthcare Conference fireside chat
◆Trial InitiationKPL-387Trial
Phase 2/3 trial initiation expected mid-2025
recurrent pericarditissource ↗
◆Quarterly UpdateCorporate
First quarter 2025 financial results and recent portfolio execution
▲Quarterly UpdateARCALYSTApprovedCorporate
ARCALYST Q1 2025 net product revenue of $137.8 million, 75% year-over-year growth
recurrent pericarditissource ↗
◆Quarterly UpdateCorporate
Q4 and full year 2024 financial results and recent portfolio execution
▼Program DiscontinuationabiprubartDiscontinuedCorporate
Discontinue development of abiprubart in Sjögren's Disease
Sjögren's Diseasesource ↗
▼Partnership / LicensemavrilimumabCorporate
Terminate exclusive license agreement for mavrilimumab with MedImmune
◆Oral PresentationPresentation
Kiniksa to present at 43rd Annual J.P. Morgan Healthcare Conference
▲Quarterly UpdateARCALYSTApprovedCorporate
ARCALYST 2025 net product revenue of $677.5 million (unaudited), ~62% YoY growth
recurrent pericarditissource ↗
▲Poster PresentationRilonaceptApprovedPresentation
Rilonacept as Monotherapy for Long-Term Recurrent pericarditis Management: Sustained Disease Control Over Three Years presented at 2025 European Society of Cardiology Congress
recurrent pericarditissource ↗
▲Runway Guidance UpdateCorporate
Cash reserves expected to fund operations into at least 2025
▲Quarterly UpdateARCALYSTApprovedCorporate
ARCALYST Q4 2024 net product revenue of $122.5 million
recurrent pericarditissource ↗
◆Oral PresentationPresentation
Kiniksa management to present at 7th Annual Evercore ISI HealthCONx Conference
◆Oral PresentationPresentation
Kiniksa management to present at Jefferies London Healthcare Conference
◆Quarterly UpdateCorporate
Third quarter 2024 financial results and recent portfolio execution
◆Enrollment UpdateabiprubartDiscontinuedTrial
Enrolling and dosing patients in Phase 2b trial of abiprubart in Sjögren's Disease
Sjögren's Diseasesource ↗
◆Oral PresentationPresentation
Kiniksa management to present at 2024 Wells Fargo Healthcare Conference
◆Quarterly UpdateCorporate
Second quarter 2024 financial results and recent portfolio execution
◆Enrollment MilestoneabiprubartDiscontinuedTrial
Phase 2b clinical trial in Sjögren's Disease enrolling patients
Sjögren's Diseasesource ↗
◆Trial InitiationabiprubartDiscontinuedTrial
Phase 2b trial planned to initiate in 2H 2024
Sjogren's Diseasesource ↗
▲Partnership / LicenseCorporate
Sponsorship of American Heart Association's Addressing Recurrent Pericarditis initiative
recurrent pericarditissource ↗
◆Management ChangeCorporate
Proposed redomiciliation from Bermuda to UK via scheme of arrangement
◆Topline ReadoutabiprubartDiscontinuedClinical Data
Topline data from Cohort 4 announced
rheumatoid arthritissource ↗
◆Full ResultsabiprubartDiscontinuedClinical Data
Final data from first three cohorts announced
rheumatoid arthritissource ↗
◆Topline ReadoutabiprubartDiscontinuedClinical Data
Phase 2 rheumatoid arthritis data from Cohort 4 expected in April 2024
rheumatoid arthritissource ↗
◆Trial InitiationabiprubartDiscontinuedTrial
New development indication for abiprubart expected in April 2024
new development indicationsource ↗
◆Topline ReadoutKPL-404Clinical Data
Phase 2 rheumatoid arthritis data from Cohort 4 expected in Q2 2024
rheumatoid arthritissource ↗
Past FDA Catalysts and PDUFA Decisions
How KNSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2022-12-31 | vixarelimab (once-monthly subcutaneous) | Phase 2b data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C47 / 100
Pipeline Score
$978M
Pipeline Value
$3.7B
Commercial Value
Overvalued
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 24%
Small Cap(rank 159 of 658)
Percentile Rank
Kiniksa Pharmaceuticals International, plc carries a moderate pipeline score (47/100), with $1.5B risk-adjusted pipeline value, led by KPL-404 in Arthritis, Rheumatoid (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $840.8M x 4.4 = $3.7B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| ARCALYST | $841M | $529M | +58.9% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KPL-404 Small moleculeCompletedNCT05198310 | Arthritis, Rheumatoid | Phase 2 | COMPLETED | 145 | May 6, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every KNSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| abiprubart | rheumatoid arthritis | Phase 2 | 2024-04-02 | final data from the first three cohorts of the clinical trialRead More | Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart - Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 - - Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further vaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Megna Michael ROfficer (CHIEF ACCOUNTING OFFICER) | Sell | -4,600 29,062 held | $80.30 | 09/03/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KNSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.9 % (12.5 %) | 181.28 M | 2.83 M | 0.3% ( 8.40 K) |
KNSA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KNSA ranks across every disease it competes in
Competitive Position is a premium feature
See how KNSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKNSA News
KNSAKiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Kiniksa Pharmaceuticals International, plc (KNSA) will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026. The presentation will be available via a live webcast on the company's website, with a replay accessible shortly after the event. Kiniksa focuses on developing therapies for unmet medical needs, particularly in cardiovascular diseases.
Read more →KNSAKiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
Kiniksa Pharmaceuticals announced its participation in the Canaccord Genuity 46th Annual Growth Conference, scheduled for August 12, 2026. Management will engage in a fireside chat at 9:00 a.m. Eastern Time, with a live webcast available on the company's website. A replay will be accessible shortly after the event.
Read more →KNSA▲ +25%on this news
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported a strong financial performance for Q2 2026, with ARCALYST achieving net product revenues of $243.6 million, reflecting a 55% increase from the previous year. The company has raised its revenue expectations for ARCALYST to between $980 and $995 million for 2026. Additionally, Phase 2 data for KPL-387 demonstrated promising results in reducing pain and inflammation.
Read more →KNSAKiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
Kiniksa Pharmaceuticals International will hold a conference call on July 28, 2026, to discuss its second quarter financial results and recent developments. The call will be accessible via webcast and telephone, with a replay available shortly after. The company focuses on developing therapies for unmet medical needs, particularly in cardiovascular indications.
Read more →KNSAKiniksa Pharmaceuticals to Present at Upcoming June 2026 Investor Conferences
Kiniksa Pharmaceuticals has announced its participation in investor conferences scheduled for June 2026. Management will engage in fireside chats, providing insights into the company's strategies and developments. The presentations will be accessible via live webcast, with replays available shortly after the events. This initiative underscores Kiniksa's commitment to transparency and investor relations.
Read more →KNSAKiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Management will conduct fireside chats, allowing for insights into the company’s strategies and offerings. Webcasts of the presentations will be available on the company’s website, ensuring stakeholders have access to key information.
Read more →KNSA▲ +23.5%on this news
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported strong financial results for Q1 2026, with ARCALYST net product revenue reaching $214.3 million, a 56% increase from the previous year. The company raised its revenue guidance for ARCALYST to between $930 million and $945 million for the year. Additionally, KPL-387 Phase 2 data is expected in the second half of 2026, with a Phase 3 trial initiation planned by year-end.
Read more →KNSAKiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
Kiniksa Pharmaceuticals International, plc will report its first quarter 2026 financial results on April 28, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time. Participants can register for the call and access a replay afterward. Kiniksa focuses on developing therapies for unmet medical needs.
Read more →KNSAKiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST (rilonacept) in Recurrent Pericarditis
Kiniksa Pharmaceuticals has launched a Direct-to-Consumer campaign called Heart’s Home, aimed at raising awareness about recurrent pericarditis and promoting their FDA-approved therapy ARCALYST. This initiative emphasizes the importance of patient education and encourages those suffering from this condition to engage in discussions with their healthcare providers about potential treatments. The campaign leverages multiple media channels, highlighting the significant impact recurrent pericarditis has on patients' lives. ARCALYST stands out as the only therapy approved specifically for the treatment and recurrence prevention of this condition.
Read more →KNSAKiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
Kiniksa Pharmaceuticals will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The presentation will be accessible via a live webcast, with a replay available shortly after. This event underscores Kiniksa's focus on improving patient outcomes through novel therapies.
Read more →KNSA▼ -8.2%on this newsshared move
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported strong financial results for Q4 and the full year 2025, with ARCALYST achieving $677.6 million in revenue. The company anticipates 2026 sales for ARCALYST to reach between $900 and $920 million. KPL-387's Phase 2 data is expected in the second half of 2026, and a Phase 1 trial for KPL-1161 is set to begin by the end of 2026. Kiniksa's financial position supports ongoing investments in its portfolio.
Read more →KNSAKiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Kiniksa Pharmaceuticals International, plc (KNSA) will host a conference call on February 24, 2026, to discuss its financial results for the fourth quarter and full year 2025. The call will be accessible via a live webcast on the company's website. Participants can register to join the conference call by telephone, receiving a confirmation email with details. Kiniksa focuses on developing treatments for diseases with unmet needs, especially in the cardiovascular sector.
Read more →KNSAKiniksa Pharmaceuticals Provides Corporate Update
Kiniksa Pharmaceuticals has reported a significant growth in net product revenue for ARCALYST, reaching $677.5 million in 2025, representing a 62% year-over-year increase. Looking ahead, the company anticipates ARCALYST revenue to range between $900 million and $920 million in 2026. Additionally, Kiniksa is in a strong financial position with a cash balance of $414.1 million as of the end of 2025. The company is also advancing its clinical trials for KPL-387 and KPL-1161, which could enhance treatment options for recurrent pericarditis patients.
Read more →KNSAKiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced its participation in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12, 2026. During the conference, Kiniksa will present at 2:15 p.m. Pacific Time. A live webcast of the presentation will be available on the company’s website, with a replay accessible within 48 hours post-event. Kiniksa is focused on developing therapies for diseases with unmet needs, particularly in the cardiovascular sector.
Read more →KNSAKiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Kiniksa Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London on November 17, 2025. The presentation will be accessible via a live webcast on the company's website, with a replay available shortly after. Kiniksa is dedicated to developing therapies for unmet medical needs, particularly in cardiovascular indications.
Read more →KNSAKiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported strong financial results for Q3 2025, with ARCALYST net product revenue reaching $180.9 million, a 61% increase year-over-year. The company raised its revenue guidance for ARCALYST to between $670 million and $675 million. Additionally, KPL-387 received Orphan Drug Designation, and the company is on track for data from its Phase 2/3 trial in 2026.
Read more →KNSAKiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
Kiniksa Pharmaceuticals International, plc (KNSA) announced a conference call scheduled for October 28, 2025, to discuss its third quarter financial results. The call will include a live webcast accessible through the company’s website and will offer interaction opportunities for investors. The company emphasizes its focus on developing therapies for unmet medical needs, particularly in cardiovascular indications.
Read more →KNSAKiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Kiniksa Pharmaceuticals has received Orphan Drug Designation from the FDA for KPL-387, aimed at treating pericarditis, including recurrent cases. This monoclonal antibody targets IL-1R1, potentially allowing for convenient monthly self-injections. Data from the ongoing Phase 2/3 trial is expected in late 2026, highlighting Kiniksa's commitment to addressing rare diseases.
Read more →KNSACorporate Presentation SEPTEMBER 2025 Forward Looking Statements 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with re
The corporate presentation outlines the ongoing investigation of KPL-387, focusing on its application for recurrent pericarditis treatment. A Phase 2 trial is assessing KPL-387’s efficacy and safety, involving up to 80 participants who have had limited success with conventional therapies. The study emphasizes the goal of transitioning patients to KPL-387 monotherapy, with preliminary endpoints focusing on treatment response and time to recurrence. A long-term extension to monitor results for up to 24 months is also detailed.
Read more →About Kiniksa Pharmaceuticals International, plc
Headquarters105 PICCADILLY, SECOND FLOOR, LONDON, W1J 7NJ
BIOPHARMAWATCH ELITE PLUS
Trade the next KNSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime